Patent · US Active

Lymphocyte function-associated antigen 3 (LFA3) variant polypeptides and methods of use thereof to treat CD2-mediated immune diseases, disorders or conditions

US12103958B2 · kind B2 · utility

0Cited by

2References

16Claims

0Family size

Assignees

PFIZER INC. · US
The Regents of the University of California · US

Inventors

Natasha Crellin · San Carlos, US
Lauren K. Ely · New York, US
Jason Robles REYES · New York, US
Chia Chi Ho · Cincinnati, US
Jeffrey A. Bluestone · San Francisco, US
Eleonora Trotta · San Francisco, US
Qizhi Tang · Oakland, US

Key dates

Filing date	Sep 28, 2020
Grant date	Oct 1, 2024
Priority date	—
Expiry date	Apr 22, 2043

Classification

Technology area (CPC G)Physics
CPC primaryG01N2333/70507
WIPO fieldMeasurement
WIPO sectorInstruments

Abstract

The invention provides LFA3 polypeptide molecules, e.g., variant LFA3 fusion polypeptide molecules. The invention includes uses, and associated methods of using the LFA3 polypeptide molecules.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.